Press Releases
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent Alvocidib in Phase 1b/2 Zella 102 Study in Patients with Myelodysplastic Syndromes (MDS)
SALT LAKE CITY, Oct. 16, 2018 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been enrolled in a Phase 1b/2 study, Zella 102, evaluating the investigational agent alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor, plus decitabine in patients with myelodysplastic syndromes (MDS). The Phase 1b/2, open-label, dose-escalation study will evaluate the safety and preliminary clinical activity of alvocidib when administered in sequence after decitabine in patients with MDS. (More)
Tolero Pharmaceuticals Announces Clinical Research Collaboration with AbbVie for Acute Myeloid Leukemia Trial
COMPANIES TO COLLABORATE ON CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFITS OF VENETOCLAX AND ALVOCIDIB COMBINATION IN RELAPSED/REFRACTORY AML
SALT LAKE CITY, August 17, 2018 -- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and oncologic diseases, has entered into a clinical research collaboration with AbbVie, a research-based global biopharmaceutical company, exploring the potential of combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent, alvocidib, for the treatment of relapsed/refractory acute myeloid leukemia (AML). (More)
TOLERO PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED WITH INVESTIGATIONAL AGENT TP-0184, AN ACTIVIN A RECEPTOR TYPE 1 (ACVR1) INHIBITOR, IN PHASE 1 STUDY OF PATIENTS WITH ADVANCED SOLID TUMORS
SALT LAKE CITY, Utah, July 25, 2018 - Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been dosed in a Phase 1 study evaluating investigational agent TP-0184, an activin A receptor type 1 (ACVR1) inhibitor, in patients with advanced solid tumors. The Phase 1, open-label, dose-escalation study will evaluate the safety, pharmacokinetics, and pharmacodynamics of TP-0184 administered orally daily for the first 21 days of a 28-day cycle across a range of doses… (More)
TOLERO PHARMACEUTICALS ADVANCES INVESTIGATIONAL AGENT ALVOCIDIB INTO SECOND STAGE OF PHASE 2 ZELLA 201 STUDY IN PATIENTS WITH RELAPSED REFRACTORY MCL-1-DEPENDENT AML
SALT LAKE CITY, July 23, 2018 - Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that it has initiated the second stage of the Phase 2 Zella 201 study evaluating the efficacy and safety of alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and mitoxantrone (ACM) in patients with relapsed or refractory MCL-1-dependent acute myeloid leukemia (AML). During Stage 2 of the study, patients will be randomized to receive the ACM regimen or cytarabine and mitoxantrone alone… (More)
TOLERO PHARMACEUTICALS PRESENTS CLINICAL DATA FOR INVESTIGATIONAL AGENT ALVOCIDIB IN PATIENTS WITH RELAPSED REFRACTORY MCL-1—DEPENDENT AML AT EHA 2018
SALT LAKE CITY, Utah, June 15, 2018 - Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced preliminary data from Zella 201, an ongoing Phase 2 study evaluating the efficacy and safety of alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and mitoxantrone in patients with relapsed or refractory MCL-1—dependent acute myeloid leukemia (AML). Findings are being presented today at the 23rd Annual Congress of the European Hematology Association (EHA), taking place June 14-17, 2018, in Stockholm, Sweden… (More)
TOLERO PHARMACEUTICALS TO PRESENT CLINICAL DATA EVALUATING INVESTIGATIONAL AGENT ALVOCIDIB IN PATIENTS WITH RELAPSED REFRACTORY MCL-1—DEPENDENT AML AT EHA 2018
SALT LAKE CITY, Utah, May 18, 2018 - Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the presentation of preliminary data from Zella 201, an ongoing Phase 2 study evaluating the efficacy and safety of alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and mitoxantrone in patients with relapsed or refractory MCL-1—dependent acute myeloid leukemia (AML). These findings will be presented at the 23rd Annual Congress of the European Hematology Association (EHA) taking place June 14-17, 2018, in Stockholm, Sweden… (More)
TOLERO PHARMACEUTICALS TO PRESENT PRECLINICAL DATA SUPPORTING APOPTOSIS—INDUCING ACTIVITY OF ALVOCIDIB IN ACUTE MYELOID LEUKEMIA
SALT LAKE CITY, April 13, 2018 /PRNewswire-USNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematologic and oncologic diseases, today announced the presentation of preclinical data supporting the apoptosis-inducing activity of alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and daunorubicin at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14-18 in Chicago.… (More)
TOLERO PHARMACEUTICALS OPENS NEW HEADQUARTERS IN LEHI
Abbreviated Paragraph: SALT LAKE CITY, November 10, 2017 -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing treatments for hematological diseases, today unveiled its new headquarters at 3900 North Traverse Blvd in Lehi, Utah. To inaugurate the facility, Chief Executive Officer and Founder David J. Bearss, Ph.D. will be joined by leadership from Tolero's parent company… (More)
TOLERO PHARMACEUTICALS ANNOUNCES PRECLINICAL DATA SUPPORTING DEVELOPMENT OF TP-1287 AND TP-3654 FOR MYC-DEPENDENT TRIPLE NEGATIVE BREAST CANCER
SALT LAKE CITY, Oct. 23, 2017 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing treatments for hematological diseases, today announced preclinical data supporting development of TP-1287 and TP-3654 in triple negative breast cancer. (More)
TOLERO PHARMACEUTICALS TO DELIVER KEYNOTE PRESENTATIONS AT THE 9TH INTERNATIONAL CONFERENCE ON LEUKEMIA AND HEMATOLOGIC ONCOLOGY
SALT LAKE CITY, Oct. 5, 2017 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematological diseases, today announced that Chief Executive Officer, David J. Bearss, Ph.D., and… (More)
TOLERO PHARMACEUTICALS TO EXPAND ENROLLMENT OF PHASE II STUDY OF ALVOCIDIB IN MCL-1–DEPENDENT AML INTO EUROPE
SALT LAKE CITY, June 21, 2017 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that it is adding European study centers to its ongoing Phase II clinical trial evaluating alvocidib… (More)
TOLERO PHARMACEUTICALS TO PRESENT SUPPORTIVE PRECLINICAL DATA FOR INVESTIGATIONAL CDK INHIBITOR ALVOCIDIB AT EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL MEETING
SALT LAKE CITY, June 15, 2017 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the Company will present preclinical data from its alvocidib program at the European Hematology Association (EHA) 22nd Annual Congress, June 22-25 in Madrid. Alvocidib is an investigational inhibitor of… (More)
TOLERO PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON CDK9 INHIBITOR ALVOCIDIB AND ITS PRODRUG, TP-1287, AT AACR 2017
SALT LAKE CITY, UT --Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, presented preclinical data on alvocidib, an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), in Phase II development for relapsed/refractory acute myeloid leukemia (AML) and its prodrug, TP-1287… (More)
SUMITOMO DAINIPPON PHARMA COMPLETES ACQUISITION OF TOLERO PHARMACEUTICALS, INC. (US BIOTECHNOLOGY COMPANY)
January 26, 2017 - Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan; President: Masayo Tada; Securities Code: 4506, First Section of TSE, "Sumitomo Dainippon Pharma") announced today that it has completed the acquisition of Tolero Pharmaceuticals, Inc. (Head office: Lehi, UT, U.S., CEO: David J. Bearss, "Tolero") as of January 25, 2017 (U.S. Pacific Standard Time)… (More)
SUMITOMO DAINIPPON PHARMA TO ACQUIRE TOLERO PHARMACEUTICALS, INC. (US BIOTECHNOLOGY COMPANY)
December 21, 2016 - Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan; President: Masayo Tada; Securities Code: 4506, First Section of TSE, "Sumitomo Dainippon Pharma") announced today that the company and Tolero Pharmaceuticals, Inc. (Head office: Lehi, UT, U.S., CEO: David J. Bearss., "Tolero") have reached an agreement on December 21, 2016 on the acquisition of Tolero through U.S. Holding company wholly owned by Sumitomo Dainippon Pharma… (More)
